Reuters logo
BRIEF-Xynomic Pharma acquires global rights of Boehringer Ingelheim's BI 882370
October 30, 2017 / 4:40 PM / 25 days ago

BRIEF-Xynomic Pharma acquires global rights of Boehringer Ingelheim's BI 882370

Oct 30 (Reuters) - Xynomic Pharma

* Xynomic Pharma acquires global rights of Boehringer Ingelheim’s BI 882370, a novel and potent RAF inhibitor against solid tumors

* Xynomic Pharma says under terms of agreement, Xynomic will pay upfront, milestone and royalty payments up to approximately $502 million​ Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below